BridgeBio Pharma, Inc. (BBIO) stock
BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$77.36−0.94 (-1.20%)
Close on Nov 16, 2026Market cap $15.07BP/E –Yield –
BridgeBio Pharma total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
BridgeBio Pharma's total debt was $0 at Jun 30, 2025. For fiscal 2024 it was $437.34M, down 2.0% from the year before. The highest annual figure on record is $446.45M in fiscal 2023.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $437.34M | -2.0% |
| FY2023 | Dec 31, 2023 | $446.45M | +3.6% |
| FY2022 | Dec 31, 2022 | $430.99M | +0.1% |
| FY2021 | Dec 31, 2021 | $430.75M | +358.8% |
| FY2020 | Dec 31, 2020 | $93.88M | +2.3% |
| FY2019 | Dec 31, 2019 | $91.79M | +68.4% |
| FY2018 | Dec 31, 2018 | $54.51M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2025 | Jun 30, 2025 | $0 | -100.0% |
| Q1 FY2025 | Mar 31, 2025 | $0 | -100.0% |
| Q4 FY2024 | Dec 31, 2024 | $437.34M | -2.0% |
| Q3 FY2024 | Sep 30, 2024 | $436.22M | -1.2% |
| Q2 FY2024 | Jun 30, 2024 | $435.45M | -1.1% |
| Q1 FY2024 | Mar 31, 2024 | $434.72M | -0.2% |
| Q4 FY2023 | Dec 31, 2023 | $446.45M | +3.6% |
| Q3 FY2023 | Sep 30, 2023 | $441.72M | +1.8% |
| Q2 FY2023 | Jun 30, 2023 | $440.50M | +2.3% |
| Q1 FY2023 | Mar 31, 2023 | $435.76M | +322.5% |
| Q4 FY2022 | Dec 31, 2022 | $430.99M | +320.0% |
| Q1 FY2022 | Mar 31, 2022 | $434.11M | +359.8% |
| Q4 FY2021 | Dec 31, 2021 | $430.75M | +358.8% |
| Q3 FY2021 | Sep 30, 2021 | $103.14M | +10.4% |
| Q2 FY2021 | Jun 30, 2021 | $102.61M | +10.4% |
| Q1 FY2021 | Mar 31, 2021 | $94.41M | +2.2% |
| Q4 FY2020 | Dec 31, 2020 | $93.88M | +2.3% |
| Q3 FY2020 | Sep 30, 2020 | $93.39M | +24.5% |
| Q2 FY2020 | Jun 30, 2020 | $92.91M | +70.5% |
| Q1 FY2020 | Mar 31, 2020 | $92.42M | – |
| Q4 FY2019 | Dec 31, 2019 | $91.79M | – |
| Q3 FY2019 | Sep 30, 2019 | $75.02M | – |
| Q4 FY2018 | Dec 31, 2018 | $54.51M | – |
See a number that looks wrong?